15.06.2018
Upcoming event: 37C Health Meeting Stavanger
Regenics AS attends the 37C "Digitalization in Health" meeting on June 19-20 of June 2018 at Forus Stavanger. CEO Henrik Lund, co-chairs the meeting    
13.06.2018
Regenics AS Annual Report 2017
Regenics post a small positive 2017 result with topline in excess of 0.047 mill NOK. 
13.06.2018
Notice of Annual Meeting June 28th 2018
June 13th 2018 Notice of Annual Meeting June 28th 2018. The Annual Meeting 2018 will take place at the Companys site Karvesvingen 2. 2, Oslo from 2 pm to 5 pm.
23.05.2018
Innovation Norway grants Innovation Contract to Regenics AS
Regenics AS was May 18th 2018 awarded an Innovation Contract from Innovation Norway. The Innovation Contract has a total budget of 14.3 million NOK to support the development of Vernex®...
07.05.2018
Updated share info May 7th 2018
Regenics AS provides updated share info and shareowner distribution as per May 7th 2018
03.01.2018
Protocol from Extraordinary Annual Meeting December 15th 2017
December 15th 2017 Protocoll of Extraordinary Annual Meeting December 15th 2017. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
03.01.2018
Succesfull placement of share issue December 2017
According to resolutions by the Board of Directors on December 15th 2017 a limited private placement of a total of 129.729 shares at a price of 17.15 NOK per share...
27.11.2017
Japan-US researchers shows pacific roe boosting collagen mRNA production in skin cells
Pacific chum salmon roe extracts show boosting of collagen I mRNA production in skin cells and induction of anti-oxidative genes.
06.11.2017
Phillippe Collas awarded research grant from the Norwegian Cancer Society
The Norwegian Cancer Society (kreftforeningen.no), has November 3rd 2017 awarded 6 mill NOK to Professor Philippe Collas, University of Oslo for the project (norwegian): "Nytt klassifiseringsverktøy for brystkreft".
18.10.2017
New SME Instrument 2 application submitted
October 18th 2017, Regenics submits its second  SME Instruments 2 funding application for Vernex® in psoriasis based on EU Commision Seal of Excellence" project obtained July 17th 2017.
04.10.2017
New Eurostars application for Regenics
September 18th 2017, Regenics submits its second  Eurostars R&D funding application for Vernex® in psoriasis based on EU Commision Seal of Excellence" project.
30.08.2017
EU Commision upgrades "Seal of Excellence" projects for funding
EU Commision urges national bodies to fund Horizon 2020 "Seal of Excellence" projects throug a press release of May 17th 2017
30.08.2017
Protocoll from Annual Meeting June 27th 2017
June 27th 2017 Protocoll of Annual Meeting June 27nd 2017. The Annual Meeting 2017 took place in the Companys office, Karvesvingen. 2, Oslo
17.08.2017
Notice of Annual Meeting June 27nd 2017
June 20th 2017 Notice of Annual Meeting June 27nd 2017. The Annual Meeting 2016 will take place in the Companys office, Karvesvingen. 2, Oslo at 5 pm.
15.08.2017
Japan patent issued
Regenics marine technology has been granted Japanese patent on July 21st 2017
28.07.2017
Research Council grant PES 2020
Regenics AS was today awarded a contribution from the Research Council from the PES2020 program for an above treshold rating of its SME Instruments 2 application of June 2017.   
17.07.2017
Regenics wins EU Horizon 2020 Seal of Excellence
Regenics AS, Oslo, Norway, awarded with Horizon 2020 ‘Seal of Excellence’
19.06.2017
Regenics joins consortium for biological drug development receiving 16 mill SEK from Vinnova
Regenics Norway joins international consortium funded by 16 mill SEK from Vinnova, Sweden
15.03.2017
Product agreement with Farmona
Regenics has today agreed with Farmona (PL) a test production of various formulations of its biomarine cosmetic ingredient LEX.  
12.03.2017
More US news coverage of Sapelo Skin care with LEX®
Sapelo Skin Care LEX cosmetics recieves more US press
01.02.2017
Sapelo Skin Care US takes LEX® salmon roe extract to Hollywood
Sapelo Skin Care's new Salmon roe Spring Tide Serum is reported by the Hollywood Reporter as one of the new Luxe Skin Care Products, in company with diamond dust, 24-karat gold,...
11.01.2017
Additional EPO patent granted
The European Patent Office has issued an additional new patent covering Regenics AS proprietary technology. The patent was granted on November 2, 2016 as Patent Number EP 2296676. The patent expires May 7th,...
03.01.2017
New office location in Oslo
Karvesvingen 2, 0579, Oslo, Norway.   
19.12.2016
Gaselle bedrift 2016
Regenics AS one of Norways best performing companies 2016. Out of 264.000 registered businesess i Norway, 2481 companies (0.93 % of all) was selected in 2016 as "Gaselle" (gazelles) based on...

Page 1 of 4   >  >>

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.